Literature DB >> 2450351

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

T J Palker1, M E Clark, A J Langlois, T J Matthews, K J Weinhold, R R Randall, D P Bolognesi, B F Haynes.   

Abstract

A synthetic peptide (SP-10-IIIB) with an amino acid sequence [Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-Arg-Gly-Pro -Pro-Gly-(Tyr); amino acids 303-321] from the human immunodeficiency virus (HIV) isolate human T-cell lymphotropic virus type III (HTLV-III) HTLV-IIIB envelope glycoprotein gp120 was coupled to tetanus toxoid and used to raise goat antibodies to HIV gp120. Goat anti-SP-10-IIIB serum bound to the surface of HTLV-IIIB-infected CEM T cells but not to the surface of HTLV-IIIRF-infected or uninfected CEM T cells. Anti-SP-10-IIIB antibodies also selectively bound to gp120 from lysates of HTLV-IIIB cells in immunoblot assays. Twenty-one percent of sera (28 of 175) from patients seropositive for HIV contained antibodies that reacted with SP-10-IIIB in RIA. Human anti-SP-10-IIIB antibodies affinity purified from acquired immunodeficiency syndrome (AIDS) patient serum bound to HTLV-IIIB-infected cells and immunoprecipitated gp120. Goat antibodies to SP-10-IIIB neutralized HTLV-IIIB (80% neutralization titer of 1/600), inhibited HTLV-IIIB-induced syncytium formation, but did not neutralize HIV isolates HTLV-IIIRF or HTLV-IIIMN or inhibit syncytium formation with these isolates. Also, goat antiserum to an homologous synthetic peptide [SP-10-IIIRF(A), (Cys)-Arg-Lys-Ser-Ile-Thr-Lys-Gly-Pro-Gly-Arg-Val-Ile-Tyr] from gp120 of HIV isolate HTLV-IIIRF inhibited syncytium formation by HTLV-IIIRF, but did not inhibit syncytium formation by HTLV-IIIB or by HTLV-IIIMN. Thus, the amino acid sequences of SP-10-IIIB and SP-10-IIIRF(A) define homologous regions of gp120 that are important in type-specific virus neutralization. The identification of these type-specific neutralizing epitopes should facilitate the design of a polyvalent, synthetic vaccine for AIDS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450351      PMCID: PMC279895          DOI: 10.1073/pnas.85.6.1932

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients.

Authors:  M Alizon; S Wain-Hobson; L Montagnier; P Sonigo
Journal:  Cell       Date:  1986-07-04       Impact factor: 41.582

5.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

6.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Authors:  T J Matthews; A J Langlois; W G Robey; N T Chang; R C Gallo; P J Fischinger; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.

Authors:  R C Kennedy; G R Dreesman; T C Chanh; R N Boswell; J S Allan; T H Lee; M Essex; J T Sparrow; D D Ho; P Kanda
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

8.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

9.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

10.  Induction of anti-HIV neutralizing antibodies by synthetic peptides.

Authors:  T C Chanh; G R Dreesman; P Kanda; G P Linette; J T Sparrow; D D Ho; R C Kennedy
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  192 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  HIV vaccine development at Duke University Medical Center.

Authors:  B F Haynes; H X Liao; H F Staats; M S Alam; K J Weinhold; D C Montefiori
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 3.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

4.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

6.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.

Authors:  N Kato; H Sekiya; Y Ootsuyama; T Nakazawa; M Hijikata; S Ohkoshi; K Shimotohno
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.